Please provide your email address to receive an email when new articles are posted on . Preoperative chemoradiotherapy did not improve survival for individuals with resectable gastric cancer. The ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that interim results from ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the approval of durvalumab for lung cancer. The new indication applies to use of the agent with ...

CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and gemcitabine (PAXG) topped a standard option in a randomized trial of ...

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the associated factor EMP1 in the progression of resectable pancreatic cancer ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Adding novel agents to perioperative durvalumab (Imfinzi) for non-small cell lung cancer (NSCLC) led to higher rates of pathologic complete response (pCR) and major pathologic response (mPR) compared ...

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer GRAND CAYMAN, Cayman ...